Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.80 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | NPBWR1 | P48145 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7513959 | 0.89 | GRIN1 (1.00) | RIPK1GRIN1GRIN2BMAPTALDH1A1 | |
| SCHEMBL6763997 | 0.89 | RIPK1 (0.81) | RIPK1GRIN1GRIN2BMAPTALDH1A1 | |
| SCHEMBL9301921 | 0.86 | RIPK1 (0.76) | RIPK1GRIN1GRIN2BMAPTALDH1A1 | |
| SCHEMBL28642046 | 0.83 | RIPK1 (0.71) | RIPK1GRIN1GRIN2BMAPTALDH1A1 | |
| SCHEMBL29822933 | 0.83 | RIPK1 (0.71) | RIPK1GRIN1GRIN2BMAPTALDH1A1 | |
| SCHEMBL6371911 | 0.82 | RIPK1 (0.70) | RIPK1GRIN1GRIN2BMAPTALDH1A1 | |
| SCHEMBL18459774 | 0.81 | MAPT (0.76) | RIPK1GRIN1GRIN2BMAPTALDH1A1 | |
| SCHEMBL18426060 | 0.80 | MAPT (0.74) | RIPK1GRIN1GRIN2BMAPTALDH1A1 | |
| SCHEMBL6753969 | 0.80 | KDM4E (0.79) | RIPK1GRIN1GRIN2BMAPTALDH1A1 | |
| SCHEMBL9642133 | 0.80 | MAPT (1.00) | RIPK1GRIN1GRIN2BMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132467-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TMEM16A LIMITED (GB) | 2024-04-25 | — | — | US | disclosed |
| US-6828320-B2 | Enzyme inhibitors; anticancer agents | SMITHKLINE BEECHAM CORPORATION | 2004-12-07 | — | — | US | disclosed |
| US-6723726-B1 | Protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-04-20 | — | — | US | disclosed |
| EP-0912570-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2003-09-10 | — | — | EP | disclosed |
| EP-1304110-A2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2003-04-23 | — | — | EP | disclosed |
| EP-0912559-B1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2002-11-06 | — | — | EP | disclosed |
| US-20020147214-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| US-6391874-B1 | ANTICARCINOGENIC AGENTS; SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | disclosed |
| US-6174889-B1 | PROTEIN TYROSINE KINASE INHIBITORS RELATED TO BIOISOSTERES OF QUINOLINE AND QUINAZOLINE DERIVATIVES; ANTICARCINOGENIC AND -TUMOR AGENTS; PSORIASIS; RESTENOSIS; RHEUMATOID ARTHRITIS, AUTOIMMUNE DISEASE, ALLERGY, ASTHMA AND GRAFT REJECTION | GLAXO WELLCOME INC. | 2001-01-16 | — | — | US | disclosed |
| CN-1230187-A | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXO GROUP LTD (GB) | 1999-09-29 | — | — | CN | disclosed |
| EP-0912559-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| US-5874501-A | POLY(P-HYDROXYSTYRENE) WITH AROMATIC MOIETY AND ALIPHATIC MOIETY WITH INORGANIC OXIDE | KEEHAN DONALD J (US) | 1999-02-23 | — | — | US | disclosed |
| WO-1998002438-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | disclosed |
| WO-1998002434-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | disclosed |
| EP-0407554-B1 | METALLIC OXIDE-OXIRANE POLYMERS AND PREPOLYMERS | KEEHAN DONALD J (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1997031047-A1 | MULTI-FUNCTIONAL OXIRANE POLYMERS | KEEHAN DONALD J (US) | 1997-08-28 | — | — | WO | disclosed |
| US-5658996-A | A LIQUID POLYEPOXIDE PREPOLYMER THE REACTION PRODUCT OF A TRISHYDROXYPHENYL, AN AROMATIC DIGLYCIDYL ETHER AND METAL OXIDE; CURABLE, LOW VISCOSITY; FORMED POLYEPOXIDE IS HEAT AND CHEMICAL RESISTANCE, ELONGATION, TOUGHNESS | KEEHAN DONALD J (US) | 1997-08-19 | — | — | US | disclosed |
| US-5169912-A | Hydrolyzable oxygen bonding with epoxide; silica, titania; high performance coatings, adhesives | KEEHAN DONALD J (US) | 1992-12-08 | — | — | US | disclosed |
| US-5026816-A | Reaction product of diglycidyl ether of (bisphenol a or resorcinol) with metallic oxide in presence of imidazole catalyst | KEEHAN DONALD J (US) | 1991-06-25 | — | — | US | disclosed |
| US-4880892-A | PHOSPHONIUM OR PHOSPHORANE CATALYST, PROTECTIVE COATINGS | CIBA-GEIGY CORPORATION (US) | 1989-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147214-A1 | Heterocyclic compounds | BRAF, ABL1, CSK | RIPK1 405/4885GRIN1 4085/4885GRIN2B 4209/4885 |
| US-20240132467-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TMEM109, CFTR, TMEM164 | RIPK1 3766/4885GRIN1 1267/4885GRIN2B 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.